FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 622 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 COVID-19: “It could take months to build research up again” July 1, 2020 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line... May 18, 2026 Load more HOT NEWS Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for... Can Immunotherapy Succeed in Glioblastoma? Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene
